What is the RNAZ stock price prediction for next 2 weeks?

According to our price prediction algorithm,TransCode Therapeutics, Inc. (RNAZ) price will be around $7.05 in the next 2 weeks. This means it will decrease by -11.998751560549314 from the last closing price. This prediction may vary from other time period filters for RNAZ stock.

What can be the highest Possible price of RNAZ stock in next 2 weeks?

Our forecast algorithm expects that in 2 weeks, RNAZ can achieve the highest price of $7.74 which is -3.3892756721398727 lower than last closing price. This prediction may vary from other time period filters for RNAZ stock.

What can be the lowest Possible price of RNAZ stock in next 2 weeks?

As per the forecast and algorithmic analysis, RNAZ stock price can be as low as $6.33 which is -21.01262268211878 lower than the current price in the next 2 weeks. This prediction may vary from other time period filters for RNAZ stock.

Will RNAZ stock go high in the next 2 weeks?

No, our stock forecasting algorithm shows that RNAZ stock will lose-11.998751560549314 in the next 2 weeks. This prediction may vary from other time period filters for RNAZ stock.

What is RNAZ stock last closing price?

Last closing price of RNAZ stock was $8.01.

What is RNAZ stock price prediction?

RNAZ stock price prediction means predicting the future closing prices of RNAZ stock based on its past data. Our forecasting algorithm uses various machine learning and deep learning techniques to forecast the future behavior of RNAZ stock in a certain time period.

How we predict RNAZ stock future prices?

If you are searching for RNAZ stock forecast, analysis or price prediction, then you might be wondering what TransCode Therapeutics, Inc. (RNAZ) will do in the future. Our RNAZ price predictions are based on various Machine Learning based algorithms with an aim to try and predict future price movements. This RNAZ price prediction will likely answer most of your questions.

How frequent we update RNAZ stock predictions?

We are updating the forecasts for the RNAZ stock on daily basis.

Is using ML forecasting for RNAZ stock a good way?

Yes. Stock Price Prediction is one of the most exciting applications of Machine Learning. By leveraging data from the past, it is possible to use forecasting models to make accurate predictions about future stock prices. This can be incredibly beneficial for investors and traders, as it gives them the ability to make more informed decisions about when to buy and sell. Investing in the stock market can be a risky endeavor, but leveraging Machine Learning can make it a bit less daunting and more profitable.

Is the Prediction for RNAZ stock same for all the time periods?

No, the prediction for RNAZ stock is not same for all time periods. The forecasts may vary depending on the differences in the time period.

TransCode Therapeutics, Inc. Stock Forecast and Stock Price Prediction

Stock Forecast Chart

Stock Price Prediction Summary

Closed Price$8.0115.09%Since 2 Weeks

Predicted Price$7.05-12%For 2 Weeks

Upper Predicted Price$7.74-3.39%For 2 Weeks

Lower Predicted Price$6.33-21.01%For 2 Weeks

Forecast Score Based on 2 Weeks

Based on our forecast, the price of RNAZ will decline by -12.00% over the next 2 Weeks and hit $7.05 by Friday, January 23, 2026. In that time frame, RNAZ's share price is expected to range between $6.33 and $7.74.

BearishAverageBullish

Date	Predicted Lower	Predicted	Predicted Upper
Jan 23, 2026	6.33	7.05	7.74
Jan 22, 2026	6.73	7.40	8.10
Jan 21, 2026	6.38	7.06	7.82
Jan 20, 2026	6.40	7.14	7.87
Jan 19, 2026	6.42	7.15	7.89
Jan 16, 2026	6.72	7.42	8.11
Jan 15, 2026	7.06	7.77	8.44
Jan 14, 2026	6.75	7.43	8.17
Jan 13, 2026	6.78	7.51	8.20
Jan 12, 2026	6.82	7.53	8.26

RNAZ shares rose +1.01% in Friday, January 9, 2026's trading session, rising from a previous close of $7.93 to move at $8.01. The stock demonstrated notable intraday movement (see RNAZ's key stats for a full breakdown), fluctuating between $7.59 and $8.14, a +7.24% trading range. While recent weeks have seen some volatility, RNAZ has managed to secure a +15.09% gain over the past 2 weeks. The upward price movement was accompanied by decreased trading volume, with approximately 23.93K shares changing hands, 18.64K fewer than the previous session. This amounted to $191.70K in total market activity.

Will RNAZ Continue Its Downward Trend?

According to analyst ratings and projections for RNAZ, TransCode Therapeutics, Inc. shares are anticipated to decrease by -3.51%, potentially reaching $7.74 per share by January 23, 2026. Short-term technical indicators currently suggest a neutral sentiment for RNAZ. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 14 positive trading days within the past 30 sessions. Based on the RNAZ stock forecast, now is not the best time to buy RNAZ stock because its current trading price is +13.63% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on RNAZ covering social and institutional perspectives.

RNAZ Technical Momentum: Overbought, Oversold, or Neutral?

An analysis of Relative Strength Index (RSI) indicators provides insight into RNAZ's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 46.63% to 57.10%) suggest the stock is in a neutral to slightly bearish momentum phase. The 50-day RSI, at 43.07%, suggests a neutral medium-term outlook. Additionally, the 100-day RSI, at 44.18%, maintains a neutral outlook for the long term. Insights into RNAZ's shareholder base show how institutional investors are positioning themselves during these momentum shifts

TransCode Therapeutics Short-Term Forecasts

RNAZ Forecast For Next 5 Days

Our algorithm anticipates TransCode Therapeutics (RNAZ) stock could hit $6.17 by Jan 08, 2026. This represents a -22.93% rise from today's price, following a +16.11% change over the past five days.

RNAZ Forecast For Next 30 Days

Based on analysis of market trends, the outlook for TransCode Therapeutics, Inc. (RNAZ) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $5.29, which would mean a -33.96% decrease from the current price of $8.01. Projections for this period range from a high of $7.84 to a low of $2.80.

RNAZ Forecast For Next 90 Days

Our proprietary market analysis suggests predictions for TransCode Therapeutics's price over the next three months point to a drop. RNAZ stock is expected to peak at $7,995.56 on Mar 18, 2026 before potentially dipping to $0.00 on Apr 10, 2026. On average, RNAZ is likely to trade around $0.06 in the coming 90 days.

TransCode Therapeutics Stock Forecast 2025

Based on our predictive models, TransCode Therapeutics (RNAZ) is expected to trade between $0.00 and $8,150.21 throughout 2026. This would result in an average price of $0.02, potentially offering investors a -99.75% return from current levels.

TransCode Therapeutics, Inc. Monthly Forecast 2026

January 2026

According to our latest forecast models, TransCode Therapeutics, Inc. (RNAZ) is positioned to show a strong performance in January 2026. The price is predicted to move between $0.00 and $7560.27, settling at an average of $0.10. This could translate to a -98.75% loss.

February 2026

Based on current market signals, TransCode Therapeutics, Inc. is projected to trend february 2026. We forecast a trading range from $0.00 to $7524.94, with a likely average price of $0.06. Investors could expect a potential return of -99.25%.

March 2026

Our predictive algorithms indicate TransCode Therapeutics, Inc. stock may see a shift in March 2026. The expected range spans $0.00–$7995.56, with an average target of $0.03. This represents a cautious outlook and a possible loss of -99.63%.

April 2026

Analyzing established trends, TransCode Therapeutics, Inc. looks set to move in April 2026. Projections place the stock between $0.00 and $8041.49, averaging around $0.03. This suggests a -99.63% loss from current levels.

May 2026

Market indicators suggest TransCode Therapeutics, Inc. could experience notable changes during May 2026. Prices could fluctuate within $0.00 to $7246.47, with a midpoint forecast of $0.02. The stock might deliver a -99.75% loss.

June 2026

Forecasting for June 2026, models estimate that TransCode Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $7523.05, averaging $0.01. This signals a cautious trajectory with potential returns around -99.88%.

July 2026

According to our latest forecast models, TransCode Therapeutics, Inc. (RNAZ) is positioned to show a strong performance in July 2026. The price is predicted to move between $0.00 and $8150.21, settling at an average of $0.01. This could translate to a -99.88% loss.

August 2026

Based on current market signals, TransCode Therapeutics, Inc. is projected to trend august 2026. We forecast a trading range from $0.00 to $7598.80, with a likely average price of $0.01. Investors could expect a potential return of -99.88%.

September 2026

Our predictive algorithms indicate TransCode Therapeutics, Inc. stock may see a shift in September 2026. The expected range spans $0.00–$7661.16, with an average target of $0.00. This represents a cautious outlook and a possible loss of -100.00%.

October 2026

Analyzing established trends, TransCode Therapeutics, Inc. looks set to move in October 2026. Projections place the stock between $0.00 and $7768.43, averaging around $0.00. This suggests a -100.00% loss from current levels.

November 2026

Market indicators suggest TransCode Therapeutics, Inc. could experience notable changes during November 2026. Prices could fluctuate within $0.00 to $7946.06, with a midpoint forecast of $0.00. The stock might deliver a -100.00% loss.

December 2026

Forecasting for December 2026, models estimate that TransCode Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $7897.25, averaging $0.00. This signals a cautious trajectory with potential returns around -100.00%.

RNAZ's history of dividends and stock splits also plays a role in long-term investor confidence.